Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer

DISEASE CHARACTERISTICS:

* Diagnosis of endometrial carcinoma, including any of the following cellular types:

  * Mixed Mullerian carcinoma
  * Serous carcinoma
  * Clear cell carcinoma
* Primary advanced (FIGO stage III or stage IV) or metastatic recurrent disease
* Disease not curable by surgery
* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm with x-ray, physical exam, or non-spiral CT scan OR ≥ 10 mm with spiral CT scan or MRI
* No known cerebral metastases

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* Life expectancy ≥ 12 weeks
* Platelet count ≥ 100,000/mm\^3
* ANC ≥ 1,500/mm\^3
* Hemoglobin ≥ 10 g/dL
* Creatinine ≤ 1.25 times upper limit of normal (ULN)
* Bilirubin ≤ 1.25 times ULN
* AST/ALT \< 3 times ULN
* Glomerular filtration rate ≥ 50 mL/min
* LVEF ≥ 50% by ECHO
* Fertile patients must use effective contraception
* No myocardial infarction within the past 6 months
* No NYHA class II-IV congestive heart failure
* No third degree or complete heart block unless a pacemaker is in place
* No other malignancy within the past 5 years
* No concomitant medical illness (e.g., uncontrolled infection, uncontrolled angina, or other relevant illness) that makes the prescribed treatments within this study unfeasible
* No known hypersensitivity to study drugs
* No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

PRIOR CONCURRENT THERAPY:

* No prior chemotherapy for disease recurrence
* At least 12 months since prior adjuvant therapy containing anthracyclines with cumulative doses not exceeding the following:

  * Epirubicin 600 mg/m²
  * Doxorubicin 300 mg/m²
* At least 6 months since prior adjuvant therapy containing platinum
* At least 4 weeks since completion of radiotherapy involving the whole pelvis
* No concurrent radiotherapy or planned radiotherapy after study
* No concurrent endocrine, immunological, or other anticancer therapy
* No concurrent participation in another investigational drug study